Iatrogenic osteoporosis

Sep 21, 2024 by in ENDOCRINOLOGY Comments Off on Iatrogenic osteoporosis

Learning objectives • Glucocorticoids induce bone loss, lead to osteoporosis, and increase the patient’s fracture risk. • Glucocorticoid-induced bone loss and increased fracture risk can be reduced. The case study…

read more

Osteoporosis in older adults

Sep 21, 2024 by in ENDOCRINOLOGY Comments Off on Osteoporosis in older adults

Learning objectives • Osteoporosis is also common in very old age. It is often underrecognized, underdiagnosed, and undertreated. • Osteoporosis is less frequent in older men than in women, but…

read more

Premenopausal women with low bone mass

Sep 21, 2024 by in ENDOCRINOLOGY Comments Off on Premenopausal women with low bone mass

Learning objectives • There is no consensus on the diagnostic criteria of osteoporosis in premenopausal women. • The relationship between BMD and fractures is not as well established in premenopausal…

read more

Osteoporosis in men

Sep 21, 2024 by in ENDOCRINOLOGY Comments Off on Osteoporosis in men

Learning objectives Osteoporosis in men, as in women, is asymptomatic until a fracture occurs. It is very often underrecognized, underdiagnosed, and undertreated. Osteoporosis is less frequent in men than in…

read more

Atypical femoral fractures

Sep 21, 2024 by in ENDOCRINOLOGY Comments Off on Atypical femoral fractures

Learning objectives • Recognize the symptoms and presentation of atypical femoral shaft fractures (AFF). • Understand the pathophysiology of AFF and the role of antiresorptive medication. The case study Reason…

read more

Parathyroid hormone analogs

Sep 21, 2024 by in ENDOCRINOLOGY Comments Off on Parathyroid hormone analogs

Teriparatide/abaloparatide—Part I: Differences and similarities Learning objectives • Pharmacologic profile: efficacy and adverse effects of teriparatide and abaloparatide. • Teriparatide and abaloparatide: differences and similarities. • Impact of recent label…

read more

Sclerostin inhibitor (SERM): Romosozumab

Sep 21, 2024 by in ENDOCRINOLOGY Comments Off on Sclerostin inhibitor (SERM): Romosozumab

Learning objectives • Understand bone turnover, its various components, and how they can be manipulated. • Recognize the role of sclerostin and romosozumab in bone turnover. • Identify patients who…

read more

Sclerostin inhibitor (SERM): Raloxifene

Sep 21, 2024 by in ENDOCRINOLOGY Comments Off on Sclerostin inhibitor (SERM): Raloxifene

Learning objectives • Raloxifene: Therapeutic profile: efficacy and adverse effects. • Estrogen/progesterone: uses, limitations, adverse effects. The case study Reason for seeking medical help Mrs. KA, 65-year-old woman is concerned…

read more
Get Clinical Tree app for offline access